




1-yr outcomes from MANIFEST-PF registry¹

OBJECTIVE

Retrospective analysis of safety, procedural endpoints, and longterm outcomes they included all consecutive (de novo ablation) cases, inclusive of learning curve, from March 1, 2021 - May 30, 2022.

EU-PORIA REGISTRY DESIGN

- 24 European centers with 77 operators
- 1568 all-comer AF ablation patients (de novo ablation)




ENDPOINTS

- **Safety:** Acute and chronic major and minor adverse events.
- Primary effectiveness outcome: Freedom from atrial arrhythmia (AF/AFL/AT) recurrence \geq 30 sec post 3-month blanking.
- Secondary effectiveness outcome: Freedom from atrial arrhythmia (AF/AFL/AT) post 3-month blanking **AND** freedom from Class I/III AAD AND freedom from redo ablation.

ACUTE RESULTS

- Total procedure time: 61 [40-90*] min
- Fluoroscopy time: 12 [7-19] min
- PVI was performed in 100% of cases with a 99.2% acute success rate (per patient rate)
- Non-PV ablation was performed in 359 (22.8%) cases, the most common additional lesions were:





*Data presented as median (IQR)

LONG-TERM OUTCOMES

(Median Follow-Up = 367 [289-421])

• ~1 year freedom from AF/AFL/AT





^{1.} Turagam MK, Neuzil P, Schmidt B, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry. Circulation. 2003 May 18. Online ahead of print.

• In the patients that came back for a redo ablation (9.3%, 147/1568), 72.6% of PVs were durably isolated (45.5% of patients had all PVs durably isolated)

ADVERSE EVENTS

- There was a 1.9% rate of acute major adverse events, with no reported esophageal damage or PV stenosis
- There was a 4.0% rate of reported acute minor adverse events

CONCLUSIONS

In an all-comer AF patient population of the first patients undergoing ablation with FARAPULSE.

- The acute PV isolation rate was 99.2% with ~1 hour procedure times
- The 1-year freedom from AF/AFL/AT was:
 - 78.1% full patient cohort

LONG-TERM OUTCOMES (Cont.)

- 81.6% paroxysmal AF
- 71.3% persistent AF
- Similar by center FARAPULSE procedural volume
- The adverse event rates were low with no reported esophageal damage or PV stenosis



Cardiology

300 Boston Scientific Way Marlborough, MA 01752-1234 www.bostonscientific.com

Medical Professionals: 1.800.CARDIAC (227.3422) Customer Service: 1 888 272 1001

© 2023 Boston Scientific Corporation or its affiliates. All rights reserved.

All trademarks are the property of their respective owners.